Psilocybin is under clinical development by Nova Mentis BioTech and currently in Phase II for Autism Spectrum Disorder (ASD). According to GlobalData, Phase II drugs for Autism Spectrum Disorder (ASD) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Psilocybin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Psilocybin overview
Psilocybin is under development for the treatment of fragile X syndrome and autism spectrum disorder (ASD). The drug candidate is administered through oral route in the form of capsule. The drug candidate is a psychedelic drug which acts by targeting 5-hydroxytryptamine receptor 1A (5HT1A) and 5HT2A receptors.
Nova Mentis BioTech overview
Nova Mentis BioTech (Nova Mentis) a subsidiary of Nova Mentis Life Science Corp, is focused on investigating the anti-inflammatory effects of psilocybin in under-explored metabolic indications. Nova Mentis is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of Psilocybin’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
